

A1
cont.

entirety, which is a continuation-in-part of United States application serial no. 08/876,010, filed June 13, 1997, now abandoned, which is incorporated herein by reference in its entirety.

In The Claims:

After canceling Claims 1-6 without prejudice as directed in the accompanying Divisional Patent Application Transmittal, please add new Claims 7-9:

7. (New) A composition for treating an iron overload disease comprising a therapeutically effective amount of a soluble complex comprising an HFE polypeptide according to SEQ ID NO:1 and a full length, wild-type human β_2m .
8. (New) A composition for treating an iron deficiency disease comprising a therapeutically effective amount of a soluble complex comprising an HFE polypeptide according to SEQ ID NO:2 and a full length, wild-type human β_2m .
9. (New) A composition for treating an iron deficiency disease comprising administering to a patient a therapeutically effective amount of a soluble complex comprising an HFE polypeptide according to SEQ ID NO:3 and a full length, wild-type human β_2m .
-